Cord serum dipeptidyl-peptidase 4 activity in gestational diabetes
Zahra Al-Aissa
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Authors contributed equally to this work.Search for more papers by this authorKlára Rosta
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Department of Obstetrics and Fetomaternal Medicine, University Hospital Vienna, Vienna, Austria
Authors contributed equally to this work.Search for more papers by this authorOrsolya Hadarits
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Search for more papers by this authorJürgen Harreiter
Division of Endocrinology and Metabolism, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorAndrás Zóka
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorDagmar Bancher-Todesca
Department of Obstetrics and Fetomaternal Medicine, University Hospital Vienna, Vienna, Austria
Search for more papers by this authorAttila Patócs
Hungarian Academy of Sciences – Semmelweis University “Lendulet” HET Research Group, Budapest, Hungary
Search for more papers by this authorKatalin Kiss
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
Search for more papers by this authorBeatrix Sármán
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorPéter Pusztai
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorIstván Sziller
Department of Obstetrics and Gynecology, Szent Imre Teaching Hospital, Budapest, Hungary
Search for more papers by this authorJános Rigó
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Search for more papers by this authorKároly Rácz
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorAnikó Somogyi
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorAlexandra Kautzky-Willer
Division of Endocrinology and Metabolism, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
Gábor Firneisz
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Correspondence to: Gábor Firneisz, MD, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkiralyi St. 46., Budapest H-1088, Hungary. Tel.: +36208250469; fax: +3612661007; e-mail: [email protected]Search for more papers by this authorZahra Al-Aissa
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Authors contributed equally to this work.Search for more papers by this authorKlára Rosta
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Department of Obstetrics and Fetomaternal Medicine, University Hospital Vienna, Vienna, Austria
Authors contributed equally to this work.Search for more papers by this authorOrsolya Hadarits
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Search for more papers by this authorJürgen Harreiter
Division of Endocrinology and Metabolism, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorAndrás Zóka
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorDagmar Bancher-Todesca
Department of Obstetrics and Fetomaternal Medicine, University Hospital Vienna, Vienna, Austria
Search for more papers by this authorAttila Patócs
Hungarian Academy of Sciences – Semmelweis University “Lendulet” HET Research Group, Budapest, Hungary
Search for more papers by this authorKatalin Kiss
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
Search for more papers by this authorBeatrix Sármán
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorPéter Pusztai
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorIstván Sziller
Department of Obstetrics and Gynecology, Szent Imre Teaching Hospital, Budapest, Hungary
Search for more papers by this authorJános Rigó
1st Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary
Search for more papers by this authorKároly Rácz
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorAnikó Somogyi
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Search for more papers by this authorAlexandra Kautzky-Willer
Division of Endocrinology and Metabolism, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Search for more papers by this authorCorresponding Author
Gábor Firneisz
2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Correspondence to: Gábor Firneisz, MD, PhD, 2nd Department of Internal Medicine, Semmelweis University, Szentkiralyi St. 46., Budapest H-1088, Hungary. Tel.: +36208250469; fax: +3612661007; e-mail: [email protected]Search for more papers by this authorAbstract
Background
Tissue-specific dipeptidyl-peptidase 4 (DPP4) dysregulation has been described in adults with diabetes mellitus. The DPP4 -incretin system has not been studied in foetal life. In this study, DPP4 activity and glucagon-like peptide-1 (GLP-1) levels were assessed in cord blood of neonates born to women with gestational diabetes mellitus (GDM) and nondiabetic controls.
Material and methods
This study has been conducted in two Hungarian and one Austrian centres. Patients: A total of 568 pregnant women were enrolled in the study after their OGTT between the 24th and 28th gestational week. Cord blood samplings with DPP4 activity and GLP-1 level measurements were possible in 270 (DPP4: 159 control, 111 GDM) and 112 (GLP-1: 72 control, 40 GDM) cases. OGTT (24–28th gestational week) and cord blood sampling at delivery were performed. Cord serum DPP4 activity was determined in a continuous monitoring microplate-based kinetic assay, and cord plasma GLP-1 was measured using a fluorescence ELISA method.
Results
Cord serum DPP4 activity was lower in GDM [mean (95% CI): 28·07 U/L (26·32–29·82 U/L)] than in controls [31·61 U/L (29·93–33·29 U/L), MWU P = 0·0015]. Cord plasma active GLP-1 levels were close to the lower detection limit and were not altered in GDM (control: mean = 3·43 pM, 95% CI: 3·04–3·82 pM, GDM: mean = 3·61 pM, 95% CI: 2·96–4·28 pM – MWU test P = 0·6).
Conclusions
Decreased cord serum DPP4 activity in gestational diabetes mellitus might be the result of an adaptive foetal response or an early dysregulation in the entero-insular axis with consequences beyond the incretin system. Cord plasma GLP-1 levels may reflect the missing oral intake with a limited glucose sensing of L cells via the circulation in foetal life.
References
- 1Ferrara A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 2007; 30(Suppl 2): S141–6.
- 2Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care 2007; 30: 2070–6.
- 3Aiken CE, Ozanne SE. Transgenerational developmental programming. Hum Reprod Update 2014; 20: 63–75.
- 4Brenseke B, Prater MR, Bahamonde J, Gutierrez JC. Current thoughts on maternal nutrition and fetal programming of the metabolic syndrome. J Pregnancy 2013; 2013: 368461.
- 5Ruchat SM, Houde AA, Voisin G, St-Pierre J, Perron P, Baillargeon JP et al. Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics 2013; 8: 935–43.
- 6Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol 2009; 5: 401–8.
- 7Galjaard S, Devlieger R, Van Assche FA. Fetal growth and developmental programming. J Perinat Med 2013; 41: 101–5.
- 8Brumbaugh DE, Tearse P, Cree-Green M, Fenton LZ, Brown M, Scherzinger A et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013; 162: 930–6, e931.
- 9Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F et al. Pediatric nonalcoholic fatty liver disease: a clinical and laboratory challenge. World J Hepatol 2010; 2: 275–88.
- 10Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab 2012; 14: 518–22.
- 11Firneisz G, Varga T, Lengyel G, Feher J, Ghyczy D, Wichmann B et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS ONE 2010; 5: e12226.
- 12Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917–25.
- 13Varga T, Somogyi A, Barna G, Wichmann B, Nagy G, Racz K et al. Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. Pathol Oncol Res 2011; 17: 925–30.
- 14Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 2001; 438: 382–7.
- 15Flamez D, Van Breusegem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ et al. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes 1998; 47: 646–52.
- 16Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F et al. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 1998; 47: 1046–52.
- 17 International Association of D, Pregnancy Study Groups Consensus P, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva A, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676–82.
- 18Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gulmezoglu AM et al. A global reference for fetal-weight and birthweight percentiles. Lancet 2011; 377: 1855–61.
- 19Firneisz G, Lakatos PL, Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol 2001; 36: 877–80.
- 20Firneisz G, Somogyi A. Serum level of soluble CD26/dieptidyl peptidase-4 (DPP-4) activity correlates with other liver disease biomarkers both in Asian and European patients. Transl Res 2012; 160: 95–6.
- 21Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012; 159: 25–31.
- 22Aso Y. Re: serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4). Transl Res 2012; 160: 164.
- 23Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35–53.
- 24Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168–72.
- 25Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485–93.
- 26Han SJ, Kim HJ, Choi SE, Kang Y, Lee KW, Kim DJ. Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: e49–52.
- 27Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 2012; 5: 729–33.
- 28Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A et al. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 2013; 108: 313.
- 29Fujiwara H. Membrane-bound peptidases regulate human extravillous trophoblast invasion. Placenta 2007; 28(Suppl A): S70–5.
- 30Fujiwara H, Higuchi T, Sato Y, Nishioka Y, Zeng BX, Yoshioka S et al. Regulation of human extravillous trophoblast function by membrane-bound peptidases. Biochim Biophys Acta 2005; 1751: 26–32.
- 31Sato Y, Fujiwara H, Higuchi T, Yoshioka S, Tatsumi K, Maeda M et al. Involvement of dipeptidyl peptidase IV in extravillous trophoblast invasion and differentiation. J Clin Endocrinol Metab 2002; 87: 4287–96.
- 32Coustan DR, Lowe LP, Metzger BE, Dyer AR, International Association of D, Pregnancy Study G. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010; 202: 654 e651-656.
- 33Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819–37.
- 34Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356–63.
- 35Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159–69.
- 36Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663–70.
- 37Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10–8.
- 38Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131–57.
- 39Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335–43.
- 40Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585–96.
- 41Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008; 8: 532–9.
